Skip to content
Tradewind BioScience logo

Tradewind BioScience

Tradewind BioScience is a YC Winter 2018 (W18) company. Based in San Francisco, CA, USA. Team of 2.

About Tradewind BioScience

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Tradewind BioScience develops antibody therapeutics for aggressive metastatic cancers. Its lead program targets ovarian cancer with a single antibody designed to attack primary tumor cells directly while also activating the immune system's own anti-cancer response. The company pairs its drug development with companion diagnostics to identify which patients stand to benefit most from each treatment.

From the Y Combinator listing

How Tradewind BioScience describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Tradewind translates scientific insight into innovative ways of…

Our lead candidate is a multifaceted attack antibody for ovarian cancer. Our approach enables targeting primary cancer cells directly, alongside enabling the immune system's natural anti-cancer function, all with one therapeutic antibody.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
San Francisco, CA, USA
Team size
2
Status
Active
Stage
Early

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works